Advancements Towards A Treatment For Ebola

Aug 24, 2018

Eddie Sullivan
Credit Adria Botella

Eddie Sulivan, SAB Biotherapeutics president and CEO, joined Innovation to discuss the recent advancements made by his company.

SAB Biotherapeutics announced its anti-Ebola immunotherapy provided 100% protection against a lethal dose of the Ebola virus in a recent animal study published in The Journal of Infectious Diseases.

The Ebola virus disease is a severe, often fatal illness in humans. There is currently no licensed treatment proven to neutralize the virus.